Management representatives from 1,428 provider organizations are electing to deflect mounting solution delivery concerns to outsourcing vendors, according to 91%...
VANCOUVER, BC / ACCESSWIRE / November 1, 2023 / Lotus Ventures Inc. (CSE:J)(OTC:LTTSF) ("Lotus" or the "Company") a B.C. based...
BEVERLY HILLS, CA / ACCESSWIRE / November 1, 2023 / Dr. David Amron, board-certified dermatologic surgeon and renowned Lipedema specialist,...
Planegg/Martinsried, November 4, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the...
Analysis of week 36 data from Phase 2b ORIGIN study shows atacicept 150 mg substantially reduces serum Gd-IgA1 and resolves...
The first experimental agent from the enLIGHTEN™ Discovery Platform is Alpha-201-macro1, an investigational viral immunotherapy designed to activate innate immune...
Data further characterize the mechanism for Gamida Cell’s proprietary nicotinamide (NAM) technology’s expansion and enhancement of cellsBOSTON, Nov. 04, 2023...
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patientsWOBURN, Mass.,...
Allschwil, Switzerland – November 3, 2023 Idorsia Ltd (SIX: IDIA) announced today that further data for aprocitentan, Idorsia’s investigational dual...
MIAMI, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company”) a special purpose...
In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-002 2P, an investigational therapeutic cancer...
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated...
– Novel selective and reversible FGFR2 inhibitor exhibits strong potency across key primary and resistance driver mutations with potential advantages...
WILMINGTON, Del. and BOSTON, Oct. 14, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD), a clinical-stage precision oncology...
Initial results from BDTX-1535 dose escalation show durable activity in patients with NSCLC across heterogeneous EGFR mutation subtypes No new safety...
— Data demonstrate preclinical potent T cell activation and differentiated mechanism of action and enhanced clinical efficacy irrespective of PD-L1...
Panelists of Thrive 365 with MHTC Members (From Left) Ms. Lily Jasmin, Vice President of Corporate Strategy; Ms. Norhaslina Mamat,...
Flu season officially started October 1JEFFERSON CITY, Mo., Oct. 13, 2023 (GLOBE NEWSWIRE) -- The Missouri Department of Health and...
Two late-breaking high-impact oral presentations of the Phase 3 PROTECT Study of FILSPARI®(sparsentan) in IgAN and Phase 3 DUPLEX Study...
TEL AVIV, ISRAEL, Oct. 13, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc” or the “Company”), today announced the...